The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJOncoAlert Journal Club | NEOPAN: chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic cancer
In this latest episode of the VJOncoAlert Journal Club, Michel Ducreux, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses updates from the NEOPAN trial. The study evaluated FOLFIRINOX versus gemcitabine/nab-paclitaxel in 171 patients with locally advanced pancreatic cancer. FOLFIRINOX significantly improved progression-free survival (9.7 vs 7.7 months) but surprisingly didn’t improve overall survival, unlike in metastatic disease. Quality of life slightly favored FOLFIRINOX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
